1-[(4-tert-butylphenyl)methyl]-4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(4-tert-butylphenyl)methyl]-4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazine
• 化学式: C₂₈H₃₃ClN₂
• 分子量: 433.0
• InChiKey: MOYGZHXDRJNJEP-HHHXNRCGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF<br/>[FR] R(-)-2-MÉTHOXY-11-HYDROXYAPORPHINE ET SES DÉRIVÉS
  申请人：MCLEAN HOSPITAL CORP

  公开号：WO2009009083A1

  公开（公告）日：2009-01-15

  The invention features derivatives of R(-)-2-methoxy-l 1- hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

  本发明涉及R(-)-2-甲氧基-11-羟基阿波啡的衍生物及其用于治疗帕金森病、性功能障碍和抑郁障碍的方法。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Anticoagulant contrast media
  申请人：Melton J. Laura

  公开号：US20050281746A1

  公开（公告）日：2005-12-22

  The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

  本发明提供了一种新型抗凝对比剂，包括有机支架基团、有机抗凝基团和成像基团。该发明还提供了抗凝对比介质和利用新型抗凝对比剂和抗凝对比介质来可视化内部结构的方法。
• NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES
  申请人：Lal Bansi

  公开号：US20110172425A1

  公开（公告）日：2011-07-14

  The present invention relates to a novel water based process for the preparation of substituted diphenylmethyl piperazines of Formula I and pharmaceutically acceptable salts wherein X 1 and X 2 represent independently a hydrogen, a halogen, a straight or branched chain lower alkyl, alkoxy or a hydroxyl radical and R is selected from groups such as acyl, alkyl, alkenyl, aralalkyl, aralalkenyl aralkyl, and aralalkenyl or aralkenyl hydroxyalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl or its derivative comprising, reacting a compound of Formula II, with a compound of formula R—X where R is as defined above and X is suitable leaving group which includes halides, but not limiting use of other leaving groups such as tosylate, mesylate and activated acid groups such as acyl halide, anhydrides, mixed anhydrides etc. using water as a solvent, in presence of a catalyst and a base, at 25-100° C.;

  本发明涉及一种用水为基础的新型过程，用于制备化合物I的取代二苯甲基哌嗪及其药用盐，其中X1和X2分别代表氢、卤素、直链或支链低碳基、烷氧基或羟基基团，R选自酰基、烷基、烯基、芳基烷基、芳基烯基、芳基、芳基烯基或芳基羟基烷基、芳基氧基烷基、烷氧基烷基、氨基烷基或其衍生物等，包括将化合物II与化合物R-X反应，其中R如上定义，X是适当的离去基团，包括卤素等卤素，但不限于其他离去基团，如对甲苯磺酸酯、甲磺酸酯和活化酸基团，如酰卤、酸酐、混合酸酐等，使用水作为溶剂，在催化剂和碱的存在下，在25-100°C条件下进行。